Patient leaflet - Nitisinone 2 mg hard capsules
1. What Nitisinone is and what it is used for
Nitisinone contains the active substance
nitisinone. Nitisinone is used to treat:
a rare disease called hereditary tyrosinemia
type 1 in adults, adolescents and children (in any age range)
a rare disease called alkaptonuria (AKU) in
adults.
In these diseases your body is unable to
completely break down the amino acid
tyrosine (amino acids are building blocks of
our proteins), forming harmful substances.
These substances are accumulated in your
body. Nitisinone blocks the breakdown of
tyrosine and the harmful substances are not
formed.
For the treatment of hereditary tyrosinemia
type 1, you must follow a special diet while
you are taking this medicine, because
tyrosine will remain in your body. This special
diet is based on low tyrosine and
phenylalanine (another amino acid) content.
For the treatment of AKU, your doctor may
advise you to follow a special diet.
2. What you need to know before you take Nitisinone
Do not take Nitisinone
if you are allergic to nitisinone or any of the
other ingredients of this medicine (listed in
Do not breast-feed while taking this medicine, see section “Pregnancy and breast-feeding”.
Warnings and precautions
Talk to your doctor or pharmacist before
taking Nitisinone.
ophthalmologist before and regularly during
nitisinone treatment. If you get red eyes or
any other signs of effects on the eyes, contact your doctor immediately for an eye
examination. Eye problems could be a sign of inadequate dietary control (see section 4).
During the treatment, blood samples will be drawn in order for your doctor to check whether the treatment is adequate and to make sure that there are no possible side effects causing blood disorders.
If you receive Nitisinone for treatment of hereditary tyrosinemia type 1, your liver will be checked at regular intervals because the disease affects the liver.
Follow-up by your doctor should be performed every 6 months. If you experience any side effects, shorter intervals are recommended.
Other medicines and Nitisinone
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.
Nitisinone may interfere with the effect of other medicines, such as:
- Medicines for epilepsy (such as phenytoin)
- Medicines against blood clotting (such as warfarin)
Nitisinone with food
If you start treatment by taking it with food, it is recommended that you carry on taking it with food throughout your course of treatment.
Pregnancy and breast-feeding
The safety of this medicine has not been studied in pregnant and breast-feeding women. Please contact your doctor if you plan to become pregnant. If you become pregnant you should contact your doctor immediately. Do not breast-feed while taking this medicine, see section “Do not take Nitisinone”.
Driving and using machines
This medicine has minor influence on the ability to drive and use machines. However, if you experience side effects affecting your vision you should not drive or use machines until your vision is back to normal (see section 4 “Possible side effects”).
3. How to take Nitisinone
Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.
For hereditary tyrosinemia type 1, treatment with this medicine should be started and supervised by a doctor experienced in the treatment of the disease.
For hereditary tyrosinemia type 1, the recommended total daily dose is 1 mg/kg body weight administered orally. Your doctor will adjust the dose individually.
Package leaflet: Information for the user
Nitisinone
Nitisinone 2 mg hard capsules Nitisinone 5 mg hard capsules Nitisinone 10 mg hard capsules Nitisinone 20 mg hard capsules nitisinone
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
- Keep this leaflet. You may need to read it again.
- If you have any further questions, ask your doctor, pharmacist or nurse.
- This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4.
03020060P2001.04
It is recommended to administer the dose once daily.
However, due to the limited data in patients with body weight <20 kg, it is recommended to divide the total daily dose into two daily administrations in this patient population.
For AKU, the recommended dose is 10 mg once daily.
If you have problems with swallowing the capsules, you may open the capsule and mix the powder with a small amount of water, apple juice, soft food, such as apple sauce, or formula diet, including amino acid infant formula, just before you take it.
If you take more Nitisinone than you should
If you have taken more of this medicine than you should, contact your doctor or pharmacist as soon as possible.
If you forget to take Nitisinone
Do not take a double dose to make up for a forgotten dose. If you forget to take a dose, contact your doctor or pharmacist.
If you stop taking Nitisinone
If you have the impression that the medicine is not working properly, talk to your doctor. Do not change the dose or stop the treatment without talking to your doctor.
If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.
4. Possible side effects
Like all medicines, this medicine can cause side effects, although not everybody gets them.
If you notice any side effects relating to the eyes, talk to your doctor immediately to have an eye examination. Treatment with nitisinone leads to higher levels of tyrosine in the blood which can cause eye related symptoms. In patients with hereditary tyrosinemia type 1, commonly reported eye related side effects (may affect more than 1 in 100 people) caused by higher tyrosine levels are inflammation in the eye (conjunctivitis), opacity and inflammation in the cornea (keratitis), sensitivity to light (photophobia) and eye pain. Inflammation of the eyelid (blepharitis) is an uncommon side effect (may affect up to 1 in 100 people).
In AKU patients, eye irritation (keratopathy) and eye pain are very commonly reported side effects (may affect more than 1 in 10 people).
Other side effects reported in patients with hereditary tyrosinemia type 1 are listed below:
Other common side effects
Reduced number of platelets
(thrombocytopenia) and white blood cells (leukopenia), shortage of certain white blood cells (granulocytopenia).
Other uncommon side effects
- increased number of white blood cells (leucocytosis),
- itching (pruritus), skin inflammation (exfoliative dermatitis), rash.
Other side effects reported in patients with AKU are listed below:
Other common side effects
- bronchitis
- pneumonia
itching (pruritus), rash
Reporting of side effects
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via Yellow Card Scheme Website:
www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects you can help provide more information on the safety of this medicine.
5. How to store Nitisinone
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the bottle, the blister and the carton after “EXP”. The expiry date refers to the last day of that month.
Store below 30°C.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
6. Contents of the pack and other information
What Nitisinone contains
The active substance is nitisinone Nitisinone 2 mg. Each hard capsule contains 2 mg nitisinone
Nitisinone 5 mg. Each hard capsule contains 5 mg nitisinone
Nitisinone 10 mg. Each hard capsule contains 10 mg nitisinone
Nitisinone 20 mg. Each hard capsule contains 20 mg nitisinone
The other ingredients are:
Hard capsule content
Starch, pregelatinised
Stearic acid
Capsule shell
Gelatin
Titanium dioxide (E 171)
Printing ink
Shellac
Propylene glycol
Indigotine aluminum lake (E 132)
What Nitisinone looks like and contents of the pack
The hard capsules are white, opaque, imprinted with the strength “2” or “5” or “10” or “20” and the “company logo”, in dark blue. The capsule contains a white to off-white powder.
Nitisinone is available in plastic bottles with child-proof closures of 60 capsules, and OPA/Alu/PVC - Alu perforated unit dose blisters of 60 capsules.
Not all pack sizes may be marketed.
Marketing Authorisation Holder
LogixX Pharma Ltd
Merlin House, Brunel Road,
Theale, Reading,
RG7 4AB
UK
Manufacturer
Doppel Farmaceutici S.r.l.
Via Volturno 48
20089 Quinto de’ Stampi - Rozzano (MI), Italy
This leaflet was last revised in 11/2024
Detailed information on this medicine is available on the website of MHRA Website: http://www.mhra.gov.uk.
| Customer | Dipharma SA |
| Product Name | Nitisinone combi - PIL |
| Market | UK |
| Language/s | English |
| 03020060P2001.04 | |
| Manufacturer Code | N/A |
| PD Ref. | Nitisinone_UK_2mg-5mg-10m-20mg_PIL_ver01— (** to follow final proof) |
| Customer Ref. | N/A |
| Issue | 01 |
| Date | 07 November 2024 |
| SPECIFICATION DETAILS | |
| Origination | 07 November 2024 — (as Issue 01) |
| 155 x 308 mm | |
| Border | 10 mm |
| N/A | |
| Font details | Main title: Arial - Bold — 30 pt Titles: Arial - Bold — 11 pt Sub-titles: Arial - Bold — 9 pt Body copy: Arial - Regular — 9 pt |
| Black - K | |
